A randomized, placebo-controlled, double-blind study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of DS-5565 in healthy Chinese subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Mirogabalin (Primary)
Indications Kidney disorders; Neuropathic pain; Pain; Postherpetic neuralgia
Focus Adverse reactions; Pharmacokinetics
Sponsors Daiichi Sankyo Company

15 Feb 2023 Status changed from active, no longer recruiting to completed.
15 Feb 2023 Results assessing Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants published in the Advances in Therapy
30 Nov 2017 Status changed from not yet recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com